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Abstract There is conflicting evidence of the effectiveness
of montelukast in preschool wheeze. A recent Cochrane
review focused on its use in viral-induced wheeze; however,
such subgroups are unlikely to exist in real life and change
with time, recently highlighted in an international consen-
sus report. We have therefore sought to investigate the ef-
fectiveness of montelukast in all children with preschool
wheeze (viral-induced and multiple-trigger wheeze). The
PubMed, Cochrane Library, Ovid Medline and Ovid
EMBASE were screened for randomised controlled trials
(RCTs), examining the efficacy of montelukast compared
with placebo in children with the recurrent preschool
wheeze. The primary endpoint examined was frequency of
wheezing episodes. Five trials containing 3960 patients
with a preschool wheezing disorder were analysed. Meta-
analyses of studies of intermittent montelukast showed no
benefit in preventing episodes of wheeze (mean difference
(MD) 0.07, 95% confidence interval (CI) −0.14 to 0.29;
mean for montelukast 2.68 vs placebo 2.54 (p = 0.5)), re-
ducing unscheduled medical attendances (MD −0.13, 95%
CI −0.33 to 0.07; mean for montelukast 1.62 vs placebo
1.78 (p = 0.21)) and reducing oral corticosteroids (MD
−0.06, 95% CI −0.16 to 0.02; mean for montelukast 0.35
vs placebo 0.36 (p = 0.25)). The pooled results of the con-
tinuous regimen showed no significant difference in the
number of wheezing episodes between the montelukast
and placebo groups (MD −0.40, 95% CI −1.00 to 0.19;
mean for montelukast 2.05 vs placebo 2.37 (p = 0.18)).
Conclusions: This review highlights that the currently
available evidence does not support the use of montelukast
in preschool children with recurrent wheeze. We recommend
further studies to investigate if a ‘montelukast responder’ phe-
notype exists, and how these can be easily identified in the
clinical setting.
What is Known:
• Current guidelines recommend montelukast use in preschool children
with recurrent wheeze.
• A recent Cochrane review has found montelukast to be ineffective at
reducing courses of oral corticosteroids for viral-induced wheeze.
What is New:
• This meta-analysis has examined all children with preschool wheeze
and found that montelukast was not effective at preventing wheezing
episodes or reducing unscheduled medical attendances.
• A specific montelukast responder phenotype may exist, but such patients
should be sought in larger multicentre RCTs.
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Introduction
Wheeze is a common condition in childhood [1]; half of
children experience a wheezing episode by 6 years of
age [12]. Preschool wheeze is economically burdensome
on healthcare [16].
There is a large heterogeneity in the manifestation
and response to treatment in preschool wheeze [9].
Early studies of montelukast [11, 17] a leukotriene re-
ceptor antagonist, showed it to be effective and is wide-
ly prescribed for preschool wheeze across the globe [8].
In addition to the cost of montelukast, some children
may suffer from side effects without clinical benefit.
A recent Cochrane review showed montelukast to be
ineffective at reducing courses of oral corticosteroid
(OCS) in viral-induced wheeze [6]. The European
Respiratory Society (ERS) has recently highlighted the
overlap of viral-induced and multiple-trigger wheeze [5].
This meta-analysis aims to investigate the effectiveness
of montelukast in all wheezing preschool patients,
which is a more clinically relevant and ‘real-life’ group.
Methods
Criteria for considering studies for the review
Inclusion criteria include the following:
Randomised controlled trials (RCTs) investigating the ef-
fectiveness of montelukast for recurrent wheeze in preschool
children.
Children aged 6 months to 6 years with a wheezing disor-
der (not bronchiolitis) were included.
Children must have been randomised to receive
montelukast (compared to placebo), as an intermittent
(during episodes of viral upper respiratory tract infec-
tions (URTI)) or continuous therapy for 12 months.
Studies had to be conducted over a 12-month period
to eliminate any seasonal variation.
Primary outcome measure
The primary outcome measure is frequency of wheezing epi-
sodes; episodes defined as symptoms treated with beta
agonists.
Secondary outcome measures
The secondary outcome measures are as follows:
1. Unscheduled medical attendance (USMA) (visiting a
family doctor or trained healthcare professional or acci-
dent and emergency department or hospitalisation)
2. Number of OCS courses
Data sources and study selection
Trials were identified from Cochrane Library, PubMed, Ovid
MEDLINE and Ovid EMBASE databases by two indepen-
dent reviewers (HH, CB). Keywords were a combination of
free texts and MeSH subject headings (Online supplement).
The search strategy included filters to limit the results by the
study type (RCTs only) and subject age range: infant (0–
23 months) and preschool (2–5 years). No date limits were
applied. No language restriction was applied. The bibliogra-
phy of eligible trials was searched for relevant papers. The
most recent search was conducted in April 2017. The process
of study selection is shown in Fig. 1.
Assessment of risk of bias
The risk of bias and the methodological quality of each study
were assessed according to the Cochrane Collaboration’s tool.
The trials have been evaluated for the presence of risk of bias
in terms of allocation of randomisation sequence, concealment
of allocation, blinding, handling of incomplete outcome data
(online supplement), selective reporting bias and other sources
of bias. The trials were of high methodological quality; there-
fore, the risk of bias among the studies was low. Summary
assessment of the six key domains of risk of bias is presented
in Fig. 2. The study by Bacharier et al. [2] was supported by
the National Heart, Lung and Blood Institute (NHLBI). The
WAIT study [13] was supported by the Medical Research
Council and the National Institute for Health Research.
Commercial sponsors provided the drugs and placebo, but
all the final decisions were made by the NHLBI. Studies per-
formed by Valovirta and Bisgaard et al. [4] were sponsored by
Merck & Co. Inc. The study by Robertson et al. [15] was
sponsored by Merck Sharp and Dohme (Australia) Pty. Ltd.
Statistical analysis
Data for the selected outcomes were extracted and entered into
ReviewManager Software (version 5.3). Data were expressed
as a weighted mean difference (MD) and 95%CI. Fixed-effect
(FE) model was used to pool the data. Whenever there was a
heterogeneity, random-effect (RE) model was applied.
Standard deviations (SD), if they were not reported, were cal-
culated from means and 95% CI. The study results were com-
bined depending on the method of prescribing montelukast
(intermittent or continuous). In one trial, preschool and
school-age children were included [15]; we used the preschool
data only.
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Results
One hundred sixteen records were identified from all data-
bases. After completion of the study selection process, five
studies (n = 3960) met the inclusion criteria (Table 1) [2, 4,
13, 15, 18]. All studies were conducted in high-income coun-
tries except one study [18] with centres from Africa, South
America and the Middle East. Montelukast was given inter-
mittently in four studies [2, 13, 15, 18]. Intermittent
montelukast therapy was started by parents/caregivers, as a
chewable tablet or oral granules (4 or 5 mg) over 12 months.
In one study, in addition to episode-driven montelukast, daily
montelukast therapy was also investigated [18].
Intermittent use of montelukast
The number of wheezing episodes was described in three
studies [2, 13, 18]. The final study [15] reported the number
of wheezing episodes whereby a child was seen by a
healthcare professional. Trials showed no effects of
montelukast in preventing episodes of wheeze. The pooled
estimate showed no statistically significant difference
(MD = 0.07, 95% CI −0.14 to 0.29, mean for montelukast
2.68 vs placebo 2.54 (p = 0.5)). The figure shows no hetero-
geneity between the studies (Fig. 3a, p = 0.79, I2
statistic = 0%).
All studies which used montelukast intermittently reported
USMA [2, 4, 15, 18]. The overall effect was not statistically
significant (MD = −0.13, 95% CI −0.33 to 0.07, mean for
montelukast 1.62 vs placebo 1.78 (p = 0.21)). There was a
low level of heterogeneity (Fig. 3b, p = 0.30, I2 statistic 18%).
The effect of montelukast on the use of OCS was described
in three trials [2, 13, 15]. In one trial [15], only the percentage
Fig. 1 Flow chart for selection of
studies
Fig. 2 Methodological quality summary: review authors’ judgments
about each methodological quality item for each included study
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of episodes that required OCS was presented (21%
montelukast vs 24% placebo). Thus, the results could not be
entered into the meta-analysis. This trial reported no signifi-
cant difference between montelukast and placebo in reducing
Table 1 Characteristics of included studies
Author N Outcomes Side effects Notes/bias
Nwokoro et al. [13] Mk, 669
PBO, 677
P: USMA
S: Number and duration of WE, duration of
hospital stay, number of OCS courses, time to
first USMA, symptomatic days
None ● Intermittent use
● ALOX5 (5/5 and 5/x + x/x) strata
● 71.5% EVW
● 21 primary and 41 secondary care
sites in the UK
Bacharier et al. [2] MK (4 mg), 95 BIS
(1 mg), 96
PBO, 47
P: Proportion of EFDs
S: Symptom score, caregiver QOL, numbers and
time to first OCS course, number of WEs,
number of USMA, linear growth, days
missed from day care and parental work
N/A ●Intermittent use
● 2:1 randomisation
●More dropouts in Mk group
● 5 clinical centres in the USA
Bisgaard et al. [4] Mk, 278
PBO, 271
P: Number of AEE
S: Number of oral and ICS courses, duration of
episodes, percentage of days without asthma,
severity of AEE, blood eosinophil count,
proportion of patients with an AEE, time to
first AEE, asthma-related resource utilisation
1 case of vomiting due to Mk overdose ● Continuous use
● Subgroup analysis based on atopic
profile and blood eosinophil count
● 68 sites in 23 countries
Robertson et al. [15] Mk, 107 PBO, 113 P: USMA
S: Individual components of USMA, duration of
episode, symptom score, O CS and β-agonist
use, days missed from parental work and
school or childcare, number of nights with
disturbed sleep
None ● Intermittent use
●More children with history of atopy
in Mk group
● Country: Australia
Valovirta et al. [18] Daily Mk, 589
12-day Mk, 591
PBO, 591
P: Number of asthma episodes culminating in
asthma attacks
S: Symptom score, number of asthma attacks
and episodes, percentage of EFDs, difference
in efficacy between 2 regimens
1 case of somnolence due to Mk overdose ● Intermittent and continuous use
● Double dummy
● 111 multinational sites
All double-blind randomised placebo-controlled trial
Mkmontelukast, PBO placebo, P primary, S secondary,USMA unscheduled medical attendance,WEwheezing episode,CS corticosteroid, EVS episodic
viral wheeze,MTWmultiple-trigger wheeze, ALOX5 arachidonate 5-lipoxygenase, BID budesonide inhalation suspension, EFD episode-free day, QOL
quality of life, AEE asthma exacerbation episodes, ICS inhaled corticosteroid
Fig. 3 Intermittent montelukast vs placebo. a Numbers of wheezing episodes. b Unscheduled medical attendances. c Number of oral corticosteroid
courses
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the number of OCS courses (OR, 0.80; 95% CI, 0.56 to 1.15;
mean for montelukast 0.35 vs placebo 0.36 (p = 0.25)) [15].
The pooled estimate of the other two studies [2, 13] showed
that montelukast did not significantly reduce the number of
OCS courses (MD = −0.06, 95% CI −0.15 to 0.02, p = 0.14).
There was no heterogeneity between the trials (Fig. 3c,
p = 0.51, I2 statistic 0.0%).
Continuous use of montelukast
Only 2 of the 5 included studies investigated regular continu-
ous montelukast (n = 1691) [4, 18]. The pooled estimate com-
paring the number of wheezing episodes was not statistically
significant (MD = −0.40, 95% CI −1.00 to 0.19, mean for
montelukast 2.05 vs placebo 2.37 (p = 0.18)); analysis showed
that there was a substantial heterogeneity between the includ-
ed studies (Fig. 4a, p = 0.04, I2 statistic = 77%).
One study [18] described no statistically significant differ-
ence in the number of USMA between montelukast and pla-
cebo (Fig. 4b, MD = −0.04, 95% CI −0.26 to 0.18). The other
[4] showed no statistical significance in the number of patients
presenting with at least one USMA (MD = −0.11, 95% CI
−0.36 to 0.14). As outcome measures differed, the data could
not be pooled.
The number of OCS courses was reported in the study
of Bisgaard et al. only [4]. It showed no statistically sig-
nificant difference between montelukast and placebo in
reducing the number of OCS (Fig. 4c, MD = −0.11, 95%
CI −0.36 to 0.14).
Adverse events
There was no significant difference in the incidence of adverse
events between the placebo andmontelukast. Two participants
were suffered from somnolence and vomiting due to the
montelukast overdose [4, 18]. The trials indicated that adverse
events related to the intervention rare and montelukast was
safe in preschool children.
Discussion
This systematic review of pooled data shows no evi-
dence of benefit of the use of intermittent or continuous
montelukast on the number of wheezing episodes,
USMA or OCS use for recurrent wheeze in preschool
children. However, there may be subgroups of children
with preschool wheeze who do respond to montelukast,
but there were insufficient data to determine specific
phenotypes of responders, apart from one study which
did suggest a genotype which was linked with greater
response.
The clinical question is an important one. The use of
montelukast in preschool wheeze is recommended in the
British Thoracic Society (BTS) guidelines [7]; it is widely
used across the world and should only be recommended if it
is actually helpful. The added value of this study compared to
the recent Cochrane review [6] is the inclusion of all types of
preschool wheeze; therefore, more akin to real life, it therefore
Fig. 4 Continuous montelukast vs placebo. a Number of wheezing episodes. b Unscheduled medical attendances [18]. c Number of oral corticosteroid
courses [4]
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makes the clinical question more relevant and clinically appli-
cable. Our primary outcome measure was also very clinically
relevant, being number of wheezy episodes.
The recent Cochrane review [6] used courses of OCS as a
primary outcome measure; however, evidence points to the
ineffectiveness of OCS in preschool wheeze. Therefore, by
using this as an outcome measure, subtle changes in outcome
may not be picked up, due to inconsistencies of prescribing
across healthcare professionals. The use of corticosteroids in
this group of children may vary from clinician to clinician,
whereas the frequency of wheezing episodes is more accurate
and clinically applicable.
One of the disadvantages of our analysis was that there was
some heterogeneity in the outcome set in the studies chosen for
review; thus, some outcomes which we did not select were
unable to be included within the pooled analysis. For example,
in the study by Bisgaard et al. [4], we could not compare
USMAs, because in this study, they compared the proportion
of patients who had at least one USMA rather than the number
of unscheduled visits (37% for montelukast; 42% for placebo).
A further disadvantage was that although the entry criteria
of the primary studies were generally similar, there were some
differences in the baseline characteristics of the populations of
the studies. Analysis showed a significant heterogeneity be-
tween the two studies used in the meta-analysis of those given
continuous montelukast (p = 0.04, I2 statistic = 77%). The
study performed by Bisgaard et al. [4] included patients with
quite mild symptoms of asthma, compared to those included
in the study by Valovirta et al. [18]. In the latter study, the
patients had moderate-severe asthma (intermittent symptoms
as well as one course of OCS or hospitalisation in the previous
year) [18]. There was another study which analysed relatively
mild asthma [15].
The fact that our meta-analysis looked at preschool wheeze
altogether, without separation for viral-induced or multiple-
trigger wheeze, is a great strength of the current analysis com-
pared to other meta-analyses [6]. A recent international con-
sensus report disputes the use of such terms in preschool
wheeze [5], as it seems that there is huge overlap between
these phenotypes as well as change over time; thus, separating
patients in this way may not be clinically relevant. This makes
our study more clinically applicable to the general population.
A further advantage was the strict criteria for selection
meant that only those studies with the highest quality were
included, and there was subsequently little bias or doubt of
the validity of the data. However, with such stringent criteria
set, some studies were excluded which may have been useful.
This includes a number of studies which did not span
12 months. The reason for excluding such studies was to
eliminate any seasonal variation. One excluded large
multicentre multinational RCT [11] which enrolled over 600
children, given montelukast or placebo for 12 weeks, showed
improvement in episode-free days, symptoms, use of OCS,β-
agonist use and serum eosinophil counts. The population stud-
ied seemed to be >50% atopic and many suffered from daily
symptoms, maybe more akin to the previous term of multiple-
trigger wheeze. It is important, however, to note that this par-
ticular study was conducted by the pharmaceutical company
marketing montelukast.
In all primary studies, recording of the symptoms and ini-
tiating of the intervention in the intermittent montelukast stud-
ies were carried out by parents/caregivers. Although in all the
trials, the parents were contacted either through telephone or
visits, only one study provided an educational program to the
parents on recognising symptoms which were more likely to
represent respiratory tract infection and followed by wheezing
[2]. It is possible that the initiation of treatment was too long
after the onset of symptoms, causing stimulation of the im-
mune response by the virus and thus failure of the montelukast
therapy [2].
Some of the trials included children aged 6–24 months,
which could incorporate some patients with post bronchiolitis
wheeze [2, 13, 18]. This may have led to negative findings,
because a Cochrane review reported that montelukast was not
effective in reducing the incidence of recurrent wheezing,
symptom-free days or relevant usage of corticosteroid in pa-
tients with post-bronchiolitis wheezing [14]. Interestingly, two
included trials that excluded children younger than 2 years
showed significant improvements in montelukast group com-
pared with placebo group [4, 15]. Subgroup analysis showed
better outcomes for children 2 years of age and older
(p = 0.017) [18]. It is thus possible that there may have been
some exaggeration of negative results due to the inclusion of
children less than 2 years of age.
We wanted to perform subgroup analysis to check which
patients were ‘montelukast responders’, especially checking if
serum eosinophil or atopy predicted response. Unfortunately,
there were insufficient data available to analyse this. Nwokoro
et al. [13] did perform subgroup analysis and found that those
patients with ALOX5 5/5 genotype had less USMA on
montelukast comparedwith placebo, but there was some overlap
between the groups. Repeatability in further large RCTs of such
results would need to be performed for this to be convincing.
Since this meta-analysis has been performed, a further
meta-analysis has been performed comparing the effective-
ness of continuous and intermittent high-dose inhaled cortico-
steroid (ICS), with placebo and montelukast at preventing a
severe exacerbation in preschool wheeze [10]. Continuous
ICS and intermittent ICS were both found to be effective but
were also found to be significantly more effective than
montelukast at preventing a severe attack [10]. This meta-
analysis illustrated the strong and consistent evidence that
ICS is effective in preschool wheeze. This paper, as well as
our findings, may influence a change in protocol for the treat-
ment of preschool wheeze. There have also been some early
data to suggest that azithromycin therapy in severe preschool
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wheeze may prevent a severe exacerbation [3, 19], but more
work in this area is required, due to the increase in bacterial
resistance following such medication.
This meta-analysis shows that, compared with placebo,
12 months of intermittent or continuous montelukast was not
associated with significant reduction in the frequency of
wheezing episodes, USMA or need for OCS use. This may
call into question the BTS [7] recommendations for the use
montelukast in preschool wheeze.
Recommendations
No benefit was seen with montelukast for preschool wheeze
from the limited well-conducted RCTs over at least 12 months
in preschool children with recurrent wheeze. Future trials
should be adequately powered for the predefined subgroup
analysis to identify the subgroup of children most likely to
exhibit a beneficial treatment response to montelukast.
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